{"id":10739,"date":"2025-10-18T14:35:30","date_gmt":"2025-10-18T12:35:30","guid":{"rendered":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/"},"modified":"2025-10-18T14:35:31","modified_gmt":"2025-10-18T12:35:31","slug":"un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique","status":"publish","type":"post","link":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/","title":{"rendered":"Un nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique"},"content":{"rendered":"
\n
\n
\n
\n<\/figure><\/div>\n<\/div>\n

Le paludisme reste l\u2019une des principales causes de d\u00e9c\u00e8s chez les enfants en Afrique subsaharienne, tuant plus de 600\u00a0000 personnes chaque ann\u00e9e dans le monde, avec une efficacit\u00e9 limit\u00e9e des traitements et des vaccins actuellement disponibles. Aujourd’hui, un nouvel essai clinique \u00e0 un stade pr\u00e9coce a r\u00e9v\u00e9l\u00e9 qu’un nouvel anticorps monoclonal offrait une protection compl\u00e8te, d\u00e9pendante de la dose, contre le parasite du paludisme, avec des effets secondaires minimes.<\/p>\n

Des chercheurs du Centre pour le d\u00e9veloppement de vaccins et la sant\u00e9 mondiale (CVD) de l’\u00c9cole de m\u00e9decine de l’Universit\u00e9 du Maryland ont men\u00e9 l’essai sur des volontaires sains qui ont \u00e9t\u00e9 expos\u00e9s, de mani\u00e8re contr\u00f4l\u00e9e, \u00e0 des piq\u00fbres de moustiques infect\u00e9s par le parasite du paludisme.<\/p>\n

Les r\u00e9sultats ont \u00e9t\u00e9 r\u00e9cemment publi\u00e9s dans Les maladies infectieuses du Lancet<\/i>. Les chercheurs ont men\u00e9 l\u2019essai en collaboration avec le Gates Medical Research Institute.<\/p>\n

\u00ab\u00a0Malgr\u00e9 des progr\u00e8s majeurs, le paludisme continue de d\u00e9vaster les familles et les communaut\u00e9s \u00e0 travers l’Afrique\u00a0\u00bb, a d\u00e9clar\u00e9 l’auteur principal de l’\u00e9tude, Kirsten E. Lyke, MD, professeur de m\u00e9decine \u00e0 la facult\u00e9 de m\u00e9decine de l’UM et chercheuse principale au CVD. \u00ab\u00a0Ce nouvel anticorps monoclonal pourrait transformer la fa\u00e7on dont nous pr\u00e9venons le paludisme chez les jeunes enfants et les femmes enceintes. Contrairement aux vaccins qui peuvent n\u00e9cessiter plusieurs doses ou rappels, une seule injection d’un anticorps \u00e0 action prolong\u00e9e pourrait fournir une protection imm\u00e9diate, pendant des mois. C’est une fa\u00e7on fondamentalement diff\u00e9rente d’arr\u00eater l’infection avant qu’elle ne commence.\u00a0\u00bb<\/p>\n

Les anticorps monoclonaux (AcM) sont des clones de prot\u00e9ines fabriqu\u00e9s en laboratoire qui imitent les d\u00e9fenses immunitaires naturelles de l’organisme. MAM01 cible une r\u00e9gion hautement conserv\u00e9e de la prot\u00e9ine circumsporozo\u00efte de Plasmodium falciparum, une prot\u00e9ine situ\u00e9e sur la surface externe du parasite, pour bloquer l’infection avant qu’elle n’atteigne la circulation sanguine.<\/p>\n

L’essai de phase 1, en double aveugle et contr\u00f4l\u00e9 par placebo, a recrut\u00e9 38 adultes en bonne sant\u00e9 \u00e2g\u00e9s de 18 \u00e0 50 ans sans exposition pr\u00e9alable au paludisme. Les participants ont re\u00e7u une dose de MAM01 ou un placebo, puis ont \u00e9t\u00e9 expos\u00e9s \u00e0 des moustiques porteurs du paludisme, plusieurs mois apr\u00e8s l’administration. Cela a \u00e9t\u00e9 r\u00e9alis\u00e9 dans des conditions soigneusement contr\u00f4l\u00e9es connues sous le nom d\u2019\u00e9tude de provocation. Apr\u00e8s le test antipaludique, aucun des participants ayant re\u00e7u la dose la plus \u00e9lev\u00e9e d\u2019anticorps monoclonal n\u2019a d\u00e9velopp\u00e9 d\u2019infection, par rapport \u00e0 tous les participants du groupe placebo.<\/p>\n

\u00ab\u00a0Ces premiers r\u00e9sultats sugg\u00e8rent que cet anticorps monoclonal peut fournir une protection fiable contre le paludisme, qui continue de toucher de mani\u00e8re disproportionn\u00e9e les enfants qui vivent dans des pays \u00e0 revenu faible ou interm\u00e9diaire\u00a0\u00bb, a d\u00e9clar\u00e9 le co-auteur de l’\u00e9tude Matthew B. Laurens, MD, MPH, professeur de p\u00e9diatrie et directeur de l’unit\u00e9 d’essais cliniques internationaux sur le paludisme au CVD. \u00ab\u00a0Il s’agit d’une preuve de concept importante pour le domaine et d’un pas en avant pour l’\u00e9quit\u00e9 en sant\u00e9.\u00a0\u00bb<\/p>\n

Aucun \u00e9v\u00e9nement ind\u00e9sirable grave li\u00e9 au traitement n\u2019est survenu.<\/p>\n

\u00ab L’\u00e9quipe de recherche sur les maladies cardiovasculaires explore actuellement des strat\u00e9gies optimis\u00e9es de dosage et de r\u00e9duction des co\u00fbts pour rendre possible la pr\u00e9vention bas\u00e9e sur les anticorps monoclonaux dans les r\u00e9gions end\u00e9miques du paludisme \u00bb, a d\u00e9clar\u00e9 le doyen de l’\u00c9cole de m\u00e9decine de l’UM, Mark T. Gladwin, MD, qui est \u00e9galement vice-pr\u00e9sident des affaires m\u00e9dicales \u00e0 l’Universit\u00e9 du Maryland, Baltimore (UMB), et professeur \u00e9m\u00e9rite John Z. et Akiko K. Bowers. \u00ab\u00a0Les tests de ce traitement pr\u00e9ventif ont d\u00e9j\u00e0 commenc\u00e9 chez de jeunes enfants en Ouganda, sur la base des r\u00e9sultats prometteurs du premier essai men\u00e9 ici.\u00a0\u00bb<\/p>\n

James Campbell, MD, MS, directeur par int\u00e9rim du Centre pour le d\u00e9veloppement de vaccins et la sant\u00e9 mondiale, a ajout\u00e9 : \u00ab Cette \u00e9tude repr\u00e9sente un v\u00e9ritable espoir pour des millions d’enfants \u00e0 risque. La maladie cardiovasculaire est un leader mondial dans la recherche sur le paludisme depuis plus de 50 ans, et ces r\u00e9sultats font avancer notre mission visant \u00e0 \u00e9liminer cette maladie gr\u00e2ce \u00e0 une science innovante.<\/p>\n

<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

Le paludisme reste l\u2019une des principales causes de d\u00e9c\u00e8s chez les enfants en Afrique subsaharienne,<\/p>\n","protected":false},"author":1,"featured_media":10740,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[86],"tags":[2005,733,528,732,539,71,6310,1760,7168,322,1589],"class_list":["post-10739","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-les-maladies","tag-anticorps","tag-clinique","tag-dun","tag-essai","tag-linfection","tag-lors","tag-monoclonal","tag-nouvel","tag-palustre","tag-premier","tag-previent","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-50","resize-featured-image"],"yoast_head":"\nUn nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique - RVH-Synergie.org<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique - RVH-Synergie.org\" \/>\n<meta property=\"og:description\" content=\"Le paludisme reste l\u2019une des principales causes de d\u00e9c\u00e8s chez les enfants en Afrique subsaharienne,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/\" \/>\n<meta property=\"og:site_name\" content=\"RVH-Synergie\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-18T12:35:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-18T12:35:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1760790930_Un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"854\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Charles Martinez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Martinez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/\"},\"author\":{\"name\":\"Charles Martinez\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\"},\"headline\":\"Un nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique\",\"datePublished\":\"2025-10-18T12:35:30+00:00\",\"dateModified\":\"2025-10-18T12:35:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/\"},\"wordCount\":765,\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1760790930_Un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier.jpg\",\"keywords\":[\"anticorps\",\"clinique\",\"dun\",\"essai\",\"linfection\",\"lors\",\"monoclonal\",\"nouvel\",\"palustre\",\"premier\",\"pr\u00e9vient\"],\"articleSection\":[\"Les maladies\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/\",\"name\":\"Un nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique - RVH-Synergie.org\",\"isPartOf\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1760790930_Un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier.jpg\",\"datePublished\":\"2025-10-18T12:35:30+00:00\",\"dateModified\":\"2025-10-18T12:35:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#primaryimage\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1760790930_Un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1760790930_Un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier.jpg\",\"width\":1280,\"height\":854,\"caption\":\"Un nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/rvh-synergie.org\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#website\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"name\":\"RVH-Synergie.org\",\"description\":\"RVH-Synergie, site ind\u00e9pendant d'informations sur la prise en charge des addictions.\",\"publisher\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#organization\",\"name\":\"RVH-Synergie.org\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png\",\"width\":512,\"height\":512,\"caption\":\"RVH-Synergie.org\"},\"image\":{\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560\",\"name\":\"Charles Martinez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"contentUrl\":\"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg\",\"caption\":\"Charles Martinez\"},\"description\":\"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.\",\"sameAs\":[\"https:\/\/rvh-synergie.org\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Un nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique - RVH-Synergie.org","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/","og_locale":"fr_FR","og_type":"article","og_title":"Un nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique - RVH-Synergie.org","og_description":"Le paludisme reste l\u2019une des principales causes de d\u00e9c\u00e8s chez les enfants en Afrique subsaharienne,","og_url":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/","og_site_name":"RVH-Synergie","article_published_time":"2025-10-18T12:35:30+00:00","article_modified_time":"2025-10-18T12:35:31+00:00","og_image":[{"width":1280,"height":854,"url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1760790930_Un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier.jpg","type":"image\/jpeg"}],"author":"Charles Martinez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Charles Martinez","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#article","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/"},"author":{"name":"Charles Martinez","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560"},"headline":"Un nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique","datePublished":"2025-10-18T12:35:30+00:00","dateModified":"2025-10-18T12:35:31+00:00","mainEntityOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/"},"wordCount":765,"publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1760790930_Un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier.jpg","keywords":["anticorps","clinique","dun","essai","linfection","lors","monoclonal","nouvel","palustre","premier","pr\u00e9vient"],"articleSection":["Les maladies"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/","url":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/","name":"Un nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique - RVH-Synergie.org","isPartOf":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#website"},"primaryImageOfPage":{"@id":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#primaryimage"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#primaryimage"},"thumbnailUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1760790930_Un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier.jpg","datePublished":"2025-10-18T12:35:30+00:00","dateModified":"2025-10-18T12:35:31+00:00","breadcrumb":{"@id":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#primaryimage","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1760790930_Un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2025\/10\/1760790930_Un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier.jpg","width":1280,"height":854,"caption":"Un nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique"},{"@type":"BreadcrumbList","@id":"https:\/\/rvh-synergie.org\/actualites\/un-nouvel-anticorps-monoclonal-previent-linfection-palustre-lors-dun-premier-essai-clinique\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/rvh-synergie.org\/actualites\/"},{"@type":"ListItem","position":2,"name":"Un nouvel anticorps monoclonal pr\u00e9vient l\u2019infection palustre lors d\u2019un premier essai clinique"}]},{"@type":"WebSite","@id":"https:\/\/rvh-synergie.org\/actualites\/#website","url":"https:\/\/rvh-synergie.org\/actualites\/","name":"RVH-Synergie.org","description":"RVH-Synergie, site ind\u00e9pendant d'informations sur la prise en charge des addictions.","publisher":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rvh-synergie.org\/actualites\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/rvh-synergie.org\/actualites\/#organization","name":"RVH-Synergie.org","url":"https:\/\/rvh-synergie.org\/actualites\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/favicon.png","width":512,"height":512,"caption":"RVH-Synergie.org"},"image":{"@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/aa5ea98671fb4e8620f488a0795d2560","name":"Charles Martinez","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/rvh-synergie.org\/actualites\/#\/schema\/person\/image\/","url":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","contentUrl":"https:\/\/rvh-synergie.org\/actualites\/wp-content\/uploads\/2024\/09\/charles-martinez-scaled.jpg","caption":"Charles Martinez"},"description":"Bonjour, je m'appelle Charles Martinez, r\u00e9dacteur passionn\u00e9 pour le m\u00e9dia RVH-synergie.org, d\u00e9di\u00e9 aux addictions et aux maladies. Depuis plus de dix ans, j'explore et rapporte les histoires poignantes des individus confront\u00e9s \u00e0 ces d\u00e9fis, tout en sensibilisant le public aux traitements novateurs et aux progr\u00e8s scientifiques dans ce domaine. Mon engagement r\u00e9side dans l'espoir de cr\u00e9er une communaut\u00e9 inform\u00e9e et empathique, pr\u00eate \u00e0 soutenir ceux qui luttent contre ces \u00e9preuves.","sameAs":["https:\/\/rvh-synergie.org\/"]}]}},"_links":{"self":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/10739","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/comments?post=10739"}],"version-history":[{"count":0,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/posts\/10739\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media\/10740"}],"wp:attachment":[{"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/media?parent=10739"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/categories?post=10739"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rvh-synergie.org\/actualites\/wp-json\/wp\/v2\/tags?post=10739"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}